229 related articles for article (PubMed ID: 23826641)
1. Panobinostat in lymphoid and myeloid malignancies.
Khot A; Dickinson M; Prince HM
Expert Opin Investig Drugs; 2013 Sep; 22(9):1211-23. PubMed ID: 23826641
[TBL] [Abstract][Full Text] [Related]
2. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
[TBL] [Abstract][Full Text] [Related]
3. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
Richardson PG; Harvey RD; Laubach JP; Moreau P; Lonial S; San-Miguel JF
Expert Rev Clin Pharmacol; 2016; 9(1):35-48. PubMed ID: 26503877
[TBL] [Abstract][Full Text] [Related]
4. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
5. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
6. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
Duvic M; Dummer R; Becker JC; Poulalhon N; Ortiz Romero P; Grazia Bernengo M; Lebbé C; Assaf C; Squier M; Williams D; Marshood M; Tai F; Prince HM
Eur J Cancer; 2013 Jan; 49(2):386-94. PubMed ID: 22981498
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
O'Connor OA; Heaney ML; Schwartz L; Richardson S; Willim R; MacGregor-Cortelli B; Curly T; Moskowitz C; Portlock C; Horwitz S; Zelenetz AD; Frankel S; Richon V; Marks P; Kelly WK
J Clin Oncol; 2006 Jan; 24(1):166-73. PubMed ID: 16330674
[TBL] [Abstract][Full Text] [Related]
8. Panobinostat for the treatment of acute myelogenous leukemia.
Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
[TBL] [Abstract][Full Text] [Related]
9. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
Richardson PG; Laubach JP; Lonial S; Moreau P; Yoon SS; Hungria VT; Dimopoulos MA; Beksac M; Alsina M; San-Miguel JF
Expert Rev Anticancer Ther; 2015; 15(7):737-48. PubMed ID: 26051506
[TBL] [Abstract][Full Text] [Related]
10. Deacetylase inhibitors: an advance in myeloma therapy?
Laubach JP; San-Miguel JF; Hungria V; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Alsina M; Richardson PG
Expert Rev Hematol; 2017 Mar; 10(3):229-237. PubMed ID: 28076695
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
[TBL] [Abstract][Full Text] [Related]
12. Panobinostat for the Treatment of Multiple Myeloma.
Laubach JP; Moreau P; San-Miguel JF; Richardson PG
Clin Cancer Res; 2015 Nov; 21(21):4767-73. PubMed ID: 26362997
[TBL] [Abstract][Full Text] [Related]
13. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors.
Prince HM; Bishton MJ; Johnstone RW
Future Oncol; 2009 Jun; 5(5):601-12. PubMed ID: 19519200
[TBL] [Abstract][Full Text] [Related]
14. Belinostat: clinical applications in solid tumors and lymphoma.
Molife LR; de Bono JS
Expert Opin Investig Drugs; 2011 Dec; 20(12):1723-32. PubMed ID: 22046971
[TBL] [Abstract][Full Text] [Related]
15. Panobinostat for the management of multiple myeloma.
Sivaraj D; Green MM; Gasparetto C
Future Oncol; 2017 Mar; 13(6):477-488. PubMed ID: 27776419
[TBL] [Abstract][Full Text] [Related]
16. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
Prebet T; Vey N
Expert Opin Investig Drugs; 2011 Feb; 20(2):287-95. PubMed ID: 21192773
[TBL] [Abstract][Full Text] [Related]
17. Progress of HDAC inhibitor panobinostat in the treatment of cancer.
Li X; Zhang J; Xie Y; Jiang Y; Yingjie Z; Xu W
Curr Drug Targets; 2014 Jun; 15(6):622-34. PubMed ID: 24597570
[TBL] [Abstract][Full Text] [Related]
18. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Cheng T; Grasse L; Shah J; Chandra J
Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
[TBL] [Abstract][Full Text] [Related]
19. Clinical studies of histone deacetylase inhibitors.
Prince HM; Bishton MJ; Harrison SJ
Clin Cancer Res; 2009 Jun; 15(12):3958-69. PubMed ID: 19509172
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
Ellis L; Pan Y; Smyth GK; George DJ; McCormack C; Williams-Truax R; Mita M; Beck J; Burris H; Ryan G; Atadja P; Butterfoss D; Dugan M; Culver K; Johnstone RW; Prince HM
Clin Cancer Res; 2008 Jul; 14(14):4500-10. PubMed ID: 18628465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
